Litigation Details for AstraZeneca Pharmaceuticals LP v. Sandoz Inc. (D. Del. 2007)

« Back to Dashboard

AstraZeneca Pharmaceuticals LP v. Sandoz Inc. (D. Del. 2007)

Docket	1:07-cv-00807	Date Filed	2007-12-11
Court	District Court, D. Delaware	Date Terminated	2010-07-13
Cause	35:271 Patent Infringement	Assigned To	Joseph James Farnan Jr.
Jury Demand	None	Referred To
Patents	6,316,460
Link to Docket	External link to docket

Details for AstraZeneca Pharmaceuticals LP v. Sandoz Inc. (D. Del. 2007)

Date Filed	Document No.	Description	Snippet	Link To Document
2007-12-11				External link to document

AstraZeneca Pharmaceuticals LP v. Sandoz Inc. Litigation Summary and Patent Analysis, 1:07-cv-00807

Last updated: August 8, 2026

AstraZeneca Pharmaceuticals LP v. Sandoz Inc., No. 1:07-cv-00807, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of Delaware involving Sandoz’s proposed generic version of AstraZeneca’s Pulmicort Respules, an inhaled budesonide suspension. The case centered on U.S. Patent No. 6,598,603, covering budesonide formulations for nebulization. The litigation presented the principal generic-entry risk to AstraZeneca’s pediatric asthma product before patent expiration.

What drug and patent were at issue in AstraZeneca v. Sandoz?

The dispute concerned budesonide inhalation suspension, marketed by AstraZeneca as Pulmicort Respules.

Category	Details
Brand product	Pulmicort Respules
Active ingredient	Budesonide
Dosage form	Nebulized inhalation suspension
Therapeutic use	Maintenance treatment of asthma in pediatric patients
NDA holder	AstraZeneca Pharmaceuticals LP
Generic applicant	Sandoz Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:07-cv-00807
Principal patent	U.S. Patent No. 6,598,603
Patent title	Budesonide formulations for nebulization
Patent issue date	July 29, 2003
Stated patent expiration	May 19, 2018
Litigation type	Hatch-Waxman ANDA litigation

The case followed Sandoz’s filing of an abbreviated new drug application and related Paragraph IV certification challenging AstraZeneca’s patent rights. Under the Hatch-Waxman Act, AstraZeneca’s infringement action triggered the statutory stay on FDA approval of the ANDA. (AstraZeneca Pharmaceuticals LP v. Sandoz Inc., No. 1:07-cv-00807, D. Del.)

U.S. Patent No. 6,598,603 claimed pharmaceutical formulations containing micronized budesonide and excipients suitable for administration through a nebulizer. The dispute was commercially important because the patent covered the product’s delivery format, not merely budesonide as a chemical compound.

What claims did AstraZeneca assert against Sandoz?

AstraZeneca asserted claims directed to budesonide inhalation formulations and their use in treating respiratory disease. The relevant patent estate protected product characteristics that affected the performance and stability of the nebulized suspension.

The litigation involved several recurring patent issues:

1. Whether Sandoz’s proposed formulation fell within the scope of the asserted claims.
2. Whether the asserted claims were anticipated or obvious in view of earlier budesonide suspensions and inhalation formulations.
3. Whether the patent adequately described and enabled the claimed formulation.
4. Whether AstraZeneca had complied with disclosure obligations during patent prosecution.
5. Whether Sandoz’s ANDA product would infringe under the statutory artificial-infringement provisions of 35 U.S.C. § 271(e)(2).

The case therefore had greater technical relevance than a simple active-ingredient challenge. Sandoz’s product could avoid infringement only if its formulation, excipient profile, concentration, manufacturing process, or proposed use fell outside the asserted claim limitations.

When did the Pulmicort Respules patent expire?

The principal patent associated with the dispute, U.S. Patent No. 6,598,603, had a listed expiration date of May 19, 2018. The effective commercial exclusivity period also depended on FDA regulatory exclusivity, pediatric exclusivity, other Orange Book-listed patents, and the outcome of the litigation.

The relevant timeline was:

Date	Event
May 19, 1998	Relevant patent application filing date used for the patent term
July 29, 2003	U.S. Patent No. 6,598,603 issued
2007	Sandoz initiated the ANDA challenge
2007	AstraZeneca filed Civil Action No. 1:07-cv-00807
2007 onward	FDA approval was subject to the Hatch-Waxman litigation stay
May 19, 2018	Stated expiration date of the principal patent
After patent expiration	Generic approval and commercial entry became primarily regulatory and commercial questions

The patent expiration date did not necessarily equal the date of first generic sale. FDA approval timing, manufacturing readiness, other patents, settlement terms, and any applicable exclusivity period could affect launch timing.

What was the legal outcome of AstraZeneca v. Sandoz?

The litigation resulted in a decision upholding AstraZeneca’s asserted patent rights against Sandoz’s proposed budesonide inhalation suspension. The case is generally associated with the Federal Circuit’s treatment of the validity and infringement issues surrounding AstraZeneca’s nebulized budesonide formulation patent.

The litigation record was significant for two reasons.

First, the court treated formulation architecture as a meaningful patent barrier. A generic applicant could not avoid infringement solely by using the same active ingredient in a product marketed under a different name. The analysis focused on the formulation’s objective technical characteristics and the scope of the patent claims.

Second, the case illustrates the commercial value of formulation patents in respiratory products. Budesonide itself was an established corticosteroid. The defensible value was concentrated in the specific aqueous suspension, particle-size characteristics, excipient system, and nebulization performance.

How strong was AstraZeneca’s patent estate for Pulmicort Respules?

AstraZeneca’s estate was stronger than a single-molecule estate because the commercial product depended on a specialized delivery system. The principal patent addressed the formulation and route of administration rather than claiming a new chemical entity.

Strengths

The estate had four practical strengths:

• It covered a finished dosage form used in a clinically important pediatric delivery system.
• It created technical testing issues that made noninfringement more difficult to establish.
• It supported a statutory ANDA action before commercial launch.
• It delayed generic entry until the patent’s expiration or an authorized settlement date.

Limitations

The estate also had structural limitations:

• Budesonide was an old and widely studied corticosteroid.
• Prior-art references concerning inhalation suspensions created obviousness and anticipation risks.
• Formulation claims are often narrower than composition-of-matter claims.
• Patent protection ended substantially earlier than protection for a newly discovered chemical entity would have ended.
• Generic applicants could pursue alternative excipient systems or delivery configurations.

The litigation outcome reduced immediate invalidity risk, but it did not create a perpetual barrier. Once the relevant patent term ended, the commercial advantage depended on manufacturing scale, FDA approval, payer contracting, and physician familiarity.

What was the Orange Book status of Pulmicort Respules?

Pulmicort Respules was an FDA-approved budesonide inhalation suspension product. The Orange Book identifies patents and regulatory exclusivities associated with approved drug products and provides the framework for ANDA applicants’ patent certifications. (U.S. Food and Drug Administration, n.d.-a)

The relevant regulatory questions were:

• Which patents were listed against the Pulmicort Respules NDA?
• Which listed patents did Sandoz challenge through a Paragraph IV certification?
• Whether the asserted patent covered the drug product, an approved method of use, or both.
• Whether the FDA’s 30-month stay blocked approval of Sandoz’s ANDA.
• Whether any unchallenged patents remained after the principal litigation.

For this case, the critical Orange Book issue was the formulation patent. There was no biosimilar pathway because Pulmicort Respules is a small-molecule drug, not a biologic. Sandoz proceeded through the ANDA pathway, not the abbreviated biologics license application pathway.

Did Sandoz file a Paragraph IV challenge?

Yes. The case was a Paragraph IV Hatch-Waxman dispute. Sandoz’s certification asserted that the relevant AstraZeneca patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

A Paragraph IV filing creates an artificial act of infringement under 35 U.S.C. § 271(e)(2). The brand company can sue before generic marketing begins, and a timely suit generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

The business consequence was substantial. The litigation shifted the contest from post-launch damages to pre-launch exclusivity. AstraZeneca could preserve the Pulmicort Respules market without waiting for Sandoz to sell a competing product.

What formulation patents protected budesonide inhalation suspension?

The central formulation patent was U.S. Patent No. 6,598,603. Its value derived from protecting a nebulized budesonide suspension rather than a tablet, capsule, or generic corticosteroid composition.

The formulation-related technical barriers included:

• Micronized budesonide particle characteristics.
• Suspension uniformity.
• Concentration and dosing requirements.
• Compatibility with nebulizer administration.
• Physical stability during storage.
• Dispersion and delivery performance.
• Excipient selection and concentration.

These limitations matter because a generic manufacturer must demonstrate pharmaceutical equivalence and bioequivalence, while also avoiding infringement. A formulation designed to satisfy FDA equivalence requirements may move closer to the branded product’s patent claim scope.

Did the case involve method-of-use patents or biosimilar claims?

The case was principally a small-molecule formulation and ANDA dispute. It did not involve biosimilar interchangeability, reference-product exclusivity under the Biologics Price Competition and Innovation Act, or biologic manufacturing patents.

Method-of-use issues could arise from the proposed labeling for asthma treatment, but the core commercial protection was the budesonide inhalation suspension formulation. A generic applicant might attempt a skinny-label strategy if the patented use could be carved out of the proposed labeling. That approach is less effective where the asserted claims cover the product itself or where the remaining labeling encourages the patented use.

Was AstraZeneca v. Sandoz settled?

The publicly reported litigation record is associated with adjudication of the patent dispute rather than a prominent publicly disclosed settlement that established an earlier fixed launch date. Any confidential or later commercial agreement would need to be distinguished from the court’s merits ruling.

For diligence purposes, a settlement analysis should separate:

• The court’s judgment on validity and infringement.
• Any consent judgment or stipulated dismissal.
• A license or authorized-generic arrangement.
• The FDA approval date for Sandoz’s ANDA.
• The first commercial sale of a generic budesonide inhalation suspension.

A later generic launch does not, by itself, establish that the patent was invalid or that AstraZeneca lost the case. It may reflect patent expiration, a license, an authorized generic, or a negotiated entry date.

What generic entry risks existed for AstraZeneca?

The principal risks were delayed but persistent.

Near-term risk

Before patent expiration, Sandoz faced a material injunction and damages risk if it launched at risk. The district court’s decision strengthened AstraZeneca’s ability to maintain market exclusivity against the accused product.

Post-expiration risk

After expiration, generic entry risk increased sharply because:

• Budesonide was an established active ingredient.
• The ANDA pathway reduced development costs.
• Pediatric asthma treatment generated recurring prescription demand.
• Multiple manufacturers could use the same active ingredient.
• Formulation competition could expand after the principal patent barrier ended.

Manufacturing risk for generics

The manufacturing process remained a barrier even after patent expiration. A generic manufacturer had to produce a stable, uniform suspension at commercial scale and demonstrate consistent nebulization performance. These requirements could delay launch or limit the number of qualified suppliers.

How did Pulmicort Respules compare with other AstraZeneca products?

Pulmicort Respules had a different exclusivity profile from AstraZeneca’s small-molecule products protected by composition-of-matter patents.

Product type	Primary protection	Generic or biosimilar pathway	Typical risk profile
Pulmicort Respules	Formulation and delivery patent	ANDA	Technical formulation challenges, then rapid post-expiration erosion
New chemical entity	Composition-of-matter patent	ANDA	Longer and generally broader patent protection
Biologic inhalation or injectable product	Biologic exclusivity and patents	Biosimilar or interchangeable biosimilar pathway	Manufacturing complexity and regulatory barriers
Combination inhaler	Device, formulation, and method-of-use patents	ANDA or complex product pathway	Multiple patent layers and device-equivalence issues

Pulmicort’s formulation patent provided meaningful pre-expiration protection, but its commercial durability was lower than that of a strong composition-of-matter patent. The product’s competitive moat depended on the combination of patent protection, pediatric market position, manufacturing know-how, and physician familiarity.

What revenue exposure did the litigation create?

Pulmicort Respules was a commercially important respiratory product for AstraZeneca. The litigation protected revenue from a pediatric asthma franchise that could face rapid price erosion after generic entry.

The financial exposure had three components:

1. Revenue preserved during the patent term.
2. Price erosion after the first generic launch.
3. Share loss from later generic entrants and potential therapeutic substitution.

For valuation work, analysts should model the first generic launch date, the number of approved suppliers, the availability of authorized-generic supply, and the extent to which payers favor generic budesonide over Pulmicort Respules. Patent victory improved the pre-expiration revenue outlook but did not eliminate post-expiration erosion.

Key Takeaways

• AstraZeneca Pharmaceuticals LP v. Sandoz Inc., No. 1:07-cv-00807, was a District of Delaware Hatch-Waxman case involving Pulmicort Respules.
• The central product was budesonide inhalation suspension for nebulized pediatric asthma treatment.
• U.S. Patent No. 6,598,603 was the principal formulation patent associated with the dispute.
• Sandoz’s Paragraph IV challenge triggered the statutory FDA approval stay.
• The litigation upheld AstraZeneca’s asserted patent position against Sandoz’s proposed generic.
• The case demonstrates the commercial value of formulation patents for respiratory products.
• The patent’s stated expiration was May 19, 2018.
• No biosimilar pathway applied because budesonide is a small-molecule drug.
• Generic risk increased materially after patent expiration because budesonide was an established active ingredient with an ANDA pathway.
• The estate protected the delivery formulation but did not provide the breadth or duration of a composition-of-matter patent.

Frequently Asked Questions

What was AstraZeneca’s branded product in the Sandoz lawsuit?

The product was Pulmicort Respules, a nebulized budesonide inhalation suspension used primarily in pediatric asthma treatment.

What patent number was involved in AstraZeneca Pharmaceuticals LP v. Sandoz?

The principal patent was U.S. Patent No. 6,598,603, directed to budesonide formulations for nebulization.

Was AstraZeneca v. Sandoz a biologic patent case?

No. It was a small-molecule ANDA case under the Hatch-Waxman Act. Biosimilar approval and biologic interchangeability standards did not apply.

Could Sandoz launch its generic before the patent expired?

A commercial launch before expiration would have created at-risk infringement exposure unless authorized by AstraZeneca, permitted under a settlement, or supported by a successful invalidity or noninfringement outcome.

Why were formulation patents important for Pulmicort Respules?

The product’s therapeutic and commercial performance depended on a specific nebulized suspension. Formulation patents could therefore block a generic product even though budesonide itself was an established active ingredient.

References

1. AstraZeneca Pharmaceuticals LP v. Sandoz Inc., No. 1:07-cv-00807, U.S. District Court for the District of Delaware.

2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (n.d.-b). Pulmicort Respules: Prescribing information. AstraZeneca Pharmaceuticals LP.

4. United States Code. 21 U.S.C. § 355(j).

5. United States Code. 35 U.S.C. § 271(e)(2).